Literature DB >> 14632210

Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides.

Julia J Scarisbrick1, Tracey J Mitchell, Eduardo Calonje, Guy Orchard, Robin Russell-Jones, Sean J Whittaker.   

Abstract

Fifty-one mycosis fungoides samples were analyzed for microsatellite instability (MSI) using the panel of markers recommended for hereditary nonpolyposis colorectal cancer kindred and a panel we designed for cutaneous T cell lymphoma in order to compare detection rates and determine if MSI is a genome-wide phenomenon. Samples demonstrating MSI were analyzed for abnormalities of the hMLH1 gene including loss of heterozygosity, mutations, and promoter hypermethylation. MSI was detected in 16% using the hereditary nonpolyposis colorectal cancer panel and 22% with the cutaneous T cell lymphoma panel. Overall, 27% demonstrated MSI and 73% had a stable phenotype. hMLH1 gene studies did not detect loss of heterozygosity or reveal any mutations. Promoter hypermethylation was detected in nine of 14 patients with MSI, however (64%). In addition hMLH1 and hMSH2 protein expression was studied using immunohistochemical techniques. Five of nine patients with MSI and hMLH1 promoter methylation showed abnormal hMLH1 protein expression with normal hMSH2 gene expression. All other patients tested demonstrated normal hMLH1 and hMSH2 protein expression. MSI was found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) and was associated with an older age of onset of mycosis fungoides. MSI may be a consequence of hMLH1 promoter hypermethylation in mycosis fungoides patients and may prevent transcription in a subset of patients. This suggests that the development of a mutator phenotype may contribute to disease progression in mycosis fungoides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632210     DOI: 10.1046/j.1523-1747.2003.12496.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China.

Authors:  Guangxiao Li; Fulan Hu; Fengshun Yuan; Jialong Fan; Zhifu Yu; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Jiesheng Rong; Binbin Cui; Xinshu Dong; Huiping Yuan; Yashuang Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-06       Impact factor: 4.553

3.  Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.

Authors:  Christiane Querfeld; Steven T Rosen; Joan Guitart; Alfred Rademaker; David S Pezen; M Eileen Dolan; Joseph Baron; Daniel B Yarosh; Francine Foss; Timothy M Kuzel
Journal:  Clin Cancer Res       Date:  2011-07-11       Impact factor: 12.531

Review 4.  Cutaneous T-cell lymphoma: Biologic targets for therapy.

Authors:  Jaehyuk Choi; Francine Foss
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

Review 5.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 6.  The genetics of familial lymphomas.

Authors:  Rina Siddiqui; Kenan Onel; Flavia Facio; Kenneth Offit
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

7.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

8.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989

9.  Integrated genomic analysis of sézary syndrome.

Authors:  Xin Mao; Tracy Chaplin; Bryan D Young
Journal:  Genet Res Int       Date:  2011-11-24

10.  A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability.

Authors:  Daniel J Lewis; Madeleine Duvic
Journal:  JAAD Case Rep       Date:  2017-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.